Patents Issued in June 24, 2021
  • COMPOSITIONS COMPRISING MDA-7/IL-24 PROTEIN AND METHODS OF USE
    Publication number: 20210187071
    Abstract: In various aspects, the present disclosure provides methods of preventing metastasis to bone in a subject with cancer, as well as compositions and kits for use in the same. In various aspects, the present disclosure provides methods of treating bone metastasis in a subject with cancer, as well as compositions and kits for use in the same. In embodiments, compositions comprise an MDA-7/IL-24 protein.
    Type: Application
    Filed: October 26, 2018
    Publication date: June 24, 2021
    Inventors: Paul B. FISHER, Anjan K. PRADHAN, Swadesh K. DAS, Luni EMDAD
  • METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA
    Publication number: 20210187072
    Abstract: Some embodiments provided herein relate to methods and compositions for reducing the risk of relapse of a hyperproliferative disorder, such as acute myeloid leukemia (AML), in a subject in which the hyperproliferative cells of the subject exhibit a normal karyotype and/or in a subject who has been administered no more than one induction therapeutic course. Some such embodiments include the administration of a NOX2 inhibitor, such as histamine dihydrochloride (HDC), in combination with a cytokine, such as interleukin-2 (L-2).
    Type: Application
    Filed: June 20, 2019
    Publication date: June 24, 2021
    Inventors: Anna MARTNER, Fredrik Bergh THOREN, Kristoffer HELLSTRAND
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION WITH INTERFERON LAMBDA
    Publication number: 20210187073
    Abstract: Methods of treating a hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a for at least 48 weeks.
    Type: Application
    Filed: August 23, 2019
    Publication date: June 24, 2021
    Inventors: Ingrid CHOONG, Eduardo Bruno MARTINS
  • TREATMENT OF BILIARY CIRRHOSIS BASED ON OXYNTOMODULIN ANALOGUE GLP-1R/GCGR DUAL-TARGET AGONIST PEPTIDE
    Publication number: 20210187074
    Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.
    Type: Application
    Filed: October 19, 2018
    Publication date: June 24, 2021
    Inventors: Lei WANG, Jianmei OUYANG
  • TREATMENT OF PEDIATRIC TYPE 2 DIABETES MELLITUS PATIENTS
    Publication number: 20210187075
    Abstract: The present invention refers to lixisenatide for use in pediatrics.
    Type: Application
    Filed: September 22, 2020
    Publication date: June 24, 2021
    Inventors: Karin Bergmann, Agnes Hincelin-Mery, Christelle Jan
  • VIP and VIP Agonists, Nanoparticles, and Uses in Inflammatory T-Cell Mediated Disease
    Publication number: 20210187076
    Abstract: In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.
    Type: Application
    Filed: April 23, 2019
    Publication date: June 24, 2021
    Inventors: Giacomo Waller, Yiwen Li, Edmund Waller
  • GLP-1 Agonist Conjugates for Sustained Glycemic Control
    Publication number: 20210187077
    Abstract: GLP-1 agonist peptide conjugates, methods of forming the conjugates, and methods of using the conjugates are described. Peptide conjugates include a GLP-1 agonist peptide (e.g., GLP-1 or a functional equivalent thereof), a linking agent, and a targeting moiety. Linking agents can include polymeric linkers such as PEG linkers, e.g., monodisperse PEG linkers. Targeting moieties can target tissue or cell types. Targeting moieties can include sulfhydryl groups for targeting hydroxyapatite of bone tissue. Conjugates can exhibit extended plasma half-life and can target bone tissue for use as a reservoir for extended delivery of the peptide.
    Type: Application
    Filed: December 15, 2020
    Publication date: June 24, 2021
    Inventor: ALI A. HABASHI
  • PHARMACEUTICAL COMPOSITION OF INSULIN GLARGINE AND AMINO ACIDS
    Publication number: 20210187078
    Abstract: There is provided a pharmaceutical composition comprising: (a) insulin glargine, (b) at least two amino acids, and optionally (c) one or more pharmaceutically acceptable excipients. In particular, there is provided a pharmaceutical composition comprising: (a) insulin glargine, (b) arginine and isoleucine in a weight ratio of about 1:2, and optionally (c) one or more pharmaceutically acceptable excipients.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 24, 2021
    Applicant: WOCKHARDT LIMITED
    Inventors: Maharaj Kishen SAHIB, Ganesh BARHATE, Mamatha KATRGADDA
  • ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE
    Publication number: 20210187079
    Abstract: The present invention relates to oral therapy of a subject suffering from disease e.g. polycystic disease e.g. polycystic kidney disease or polycystic liver disease or PCOS or hypotension especially neurogenic orthostatic hypotension and postprandial hypotension, or intractable diarrhea or neuroendocrine tumors or carcinoid syndrome. The method of treatment comprises oral administration to the subject of a therapeutically effective amount of an oral somatostatin receptor ligand (SRL) e.g. oral octreotide. Combination therapy of oral SRLs with other drugs is also envisaged, e.g. octreotide in combination with a therapeutically effective amount of a second therapeutic agent and optionally in combination with a therapeutically effective amount of a third therapeutic agent.
    Type: Application
    Filed: January 20, 2017
    Publication date: June 24, 2021
    Inventors: Roni Mamluk, Gary Patou, Dana Gelbaum, Asi Haviv
  • PROCESS OF OBTAINING NATIVE TYPE II COLLAGEN OF AVIAN ORIGIN
    Publication number: 20210187080
    Abstract: The invention relates to a process for obtaining native type II collagen from chicken cartilage useful for preventing or alleviating symptoms of rheumatoid arthritis in humans and mammals in general. The process details the features to obtain said material, its sanitization, drying and grinding, in order to be used in an innocuous way in food supplements. The process generates a microbiologically innocuous pathogen-free product, that can be dosed without risks for its consumption in formulations.
    Type: Application
    Filed: March 15, 2018
    Publication date: June 24, 2021
    Applicant: OLNATURA S.A. DE C.V.
    Inventor: Alonso ARANDA KILIAN
  • FORMULATIONS AND DOSES OF PEGYLATED URICASE
    Publication number: 20210187081
    Abstract: Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 24, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels
  • Lyophilized Preparation
    Publication number: 20210187082
    Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 24, 2021
    Applicant: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Yuka Yamaguchi, Shinji Okabe
  • MODIFIED FACTOR VII POLYPEPTIDES FOR SUBCUTANEOUS ADMINISTRATION AND ON-DEMAND TREATMENT
    Publication number: 20210187083
    Abstract: Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 24, 2021
    Inventors: Grant E. BLOUSE, Tom KNUDSEN, Howard LEVY
  • INJECTION TECHNIQUES FOR THE TREATMENT OF CELLULITE
    Publication number: 20210187084
    Abstract: The present disclosure relates to a method of treating cellulite on a thigh or buttock in a human subject by administering an effective amount of collagenase, and then assessing the reduction in the severity of cellulite by one or more scales.
    Type: Application
    Filed: July 12, 2019
    Publication date: June 24, 2021
    Inventors: Saji VIJAYAN, Matthew W. DAVIS, Michael MCLANE, George OMBURO, Todd KIRBY
  • PHOSPHOLIPASE A2 RECEPTOR ANTIGENS AND THEIR MEDICAL USE
    Publication number: 20210187085
    Abstract: The present invention relates to a non-naturally occurring peptide comprising amino acid sequence S-V-L-T-X1-E-N-X2 (SEQ ID NO: 1), wherein X1 is any amino acid and X2 is any amino acid, which may optionally be linked to an amino acid sequence X3-I-X4-X5-E-X6 (SEQ ID NO: 5), wherein, X3, X4, X5 and X6 each denote any amino acid. The present invention further relates to the use of such peptides as a medicament such as for the prevention and treatment of kidney disease and in apheresis methods.
    Type: Application
    Filed: October 23, 2018
    Publication date: June 24, 2021
    Applicant: The University of Manchester
    Inventors: Paul BRENCHLEY, Thomas JOWITT, Maryline FRESQUET, Rachel LENNON, Sam RHODEN
  • COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS
    Publication number: 20210187086
    Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 24, 2021
    Inventor: Bruce W. LYDAY
  • TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS
    Publication number: 20210187087
    Abstract: It is disclosed herein that B cells, not dendritic cells or myeloid-derived populations, are primary human antigen presenting cells for plasmid DNA. Based on this finding, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines are co-administered with a B cell targeting agent, B-cell recruiting agent, or a monocyte or dendritic cell recruiting agent. To increase the immunogenicity of the DNA vaccines, the B cell targeting agent or B cell recruiting agent is administered at the same location where the DNA vaccine is administered. In contrast, the monocyte or dendritic cell recruiting agent can be administered in a different location, in order to recruit cells competing with the B cells for DNA uptake away from the location where the DNA vaccine is administered.
    Type: Application
    Filed: March 3, 2021
    Publication date: June 24, 2021
    Inventors: Douglas G. McNeel, Viswa T. Colluru
  • CANCER VACCINES FOR UTERINE CANCER
    Publication number: 20210187088
    Abstract: The invention relates to the field of cancer, in particular uterine cancer. In particular, it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the ARID1A, KMT2B, KMT2D, PIK3R1, and PTEN genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.
    Type: Application
    Filed: July 25, 2019
    Publication date: June 24, 2021
    Inventor: Ronald Hans Anton PLASTERK
  • Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
    Publication number: 20210187089
    Abstract: The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.
    Type: Application
    Filed: May 23, 2019
    Publication date: June 24, 2021
    Inventors: Rogerio AMINO, Pierre CHARNEAU, Catherine BLANC, Vanessa LAGAL
  • VACCINE
    Publication number: 20210187090
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to immunogenic compositions and vaccines comprising detoxified pneumolysin adsorbed onto aluminium phosphate and an improved process for the adsorption of detoxified pneumolysin onto aluminium phosphate. It additionally relates to the use of the immunogenic compositions and vaccines in the treatment or prevention of Streptococcu pneumoniae infection.
    Type: Application
    Filed: February 20, 2017
    Publication date: June 24, 2021
    Inventors: Laurence Danielle GHENNE, Dominique Ingrid LEMOINE, Frédéric MATHOT, Florence Emilie Jeanne Francoise WAUTERS
  • COMPOSITIONS AND METHODS FOR INDUCING HIV-1 ANTIBODIES
    Publication number: 20210187091
    Abstract: In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH0848) and selections therefrom, and methods for swarm immunizations using combinations of HIV-1 envelopes.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 24, 2021
    Inventors: Barton F. HAYNES, Mattia BONSIGNORI, Bette T. KORBER, Peter T. HRABER, Kevin SAUNDERS
  • STABLE VACCINE COMPOSITIONS COMPRISING INTER ALIA LIVE ATTENUATED RECOMBINANT FLAVIVIRUS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20210187092
    Abstract: Stable lyophilized immunogenic compositions include inter alia live attenuated recombinant flaviviruses, more preferably live attenuated recombinant dengue viruses, at least one carbohydrate, at least one amino acid and is particularly amenable to rapid freeze-drying treatments wherein, the composition preserves desired characteristics of a virus, including virus viability, immunogenicity and stability. The immunogenic composition is devoid of preservatives, polymers and surfactants. The methods for manufacturing the stable lyophilized immunogenic compositions are also provided.
    Type: Application
    Filed: October 10, 2018
    Publication date: June 24, 2021
    Inventors: Rajeev Mhalasakant DHERE, Leena Ravindra YEOLEKAR, Vinit KUMAR, Rohit Bapurav SONAR, Sandeep Dinkar BARASKAR, Rajeev MEHLA, Shashikant Janardan GHODEKAR
  • Vaccine Compositions
    Publication number: 20210187093
    Abstract: The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.
    Type: Application
    Filed: March 8, 2020
    Publication date: June 24, 2021
    Applicant: Bharat Biotech International Limited
    Inventors: Kandaswamy Sumathy, Krishna Murthy Ella
  • RAPID METHOD OF GENERATING LIVE ATTENUATED VACCINES
    Publication number: 20210187094
    Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 24, 2021
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Eng Eong OOI, Kenneth GOH, Swee Sen KWEK, Choon Kit TANG
  • GENETICALLY ENGINEERED FOOT AND MOUTH DISEASE VIRUS AND RELATED PROTEINS, POLYNUCLEOTIDES, COMPOSITIONS, METHODS AND SYSTEMS
    Publication number: 20210187095
    Abstract: Genetically engineered Foot and Mouth Disease Virus (FMDV) and related engineered proteins and polynucleotides, nanolipoprotein particles, compositions, methods and systems are described. The genetically engineered FMDV is modified by the strategic insertion of a protein tag into select regions of the FMDV genome which encode viral proteins that are exposed on the surface of the FMDV viral capsid. The inserted protein tag is displayed as a decoration or attachment on the viral capsid surface.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 24, 2021
    Inventors: Aida E. RIEDER, Teresa B. DE LOS SANTOS, Luis L. RODRIGUEZ, Devendra RAI, Fayna C. DIAZ-SAN SEGUNDO, Paul D. HOEPRICH
  • UNIVERSAL VACCINE FOR VIRAL DISEASES
    Publication number: 20210187096
    Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Rodolfo César BELLINZONI, Emmanuel Gérard Etienne RÉGULIER, Ana ROMO
  • BROAD SPECTRUM INFLUENZA VIRUS VACCINE
    Publication number: 20210187097
    Abstract: The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Application
    Filed: March 15, 2018
    Publication date: June 24, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
  • VACCINATION
    Publication number: 20210187098
    Abstract: Immunogenic compositions for use in and methods for protecting against Herpes Zoster (shingles).
    Type: Application
    Filed: April 27, 2018
    Publication date: June 24, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Cornelia OOSTVOGELS
  • ANTIGEN VARIANT OF VARICELLA ZOSTER VIRUS AND USE THEREOF
    Publication number: 20210187099
    Abstract: An antigen variant and a use thereof are disclosed. The antigen variant is a protein, among surface proteins (gE) of the varicella zoster virus, exhibits a high expression level and high immunogenicity, and thus, when the antigen variant is used as a vaccine composition, the vaccine composition has more excellent safety compared to a live virus vaccine, and the antigen variant exhibits a higher expression level in a host cell compared to other antigens. The antigen variant is useful as a vaccine for preventing or treating chicken pox or herpes zoster caused by the varicella zoster virus.
    Type: Application
    Filed: May 22, 2019
    Publication date: June 24, 2021
    Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Hyo Jung NAM, Ga Young JI, Eunmi KIM
  • Storage Improved Poxvirus Compositions
    Publication number: 20210187100
    Abstract: The present invention provides storage optimized aqueous compositions comprising a poxvirus suitable as poxvirus vaccine and pharmaceutical compositions, in particular liquid compositions or liquid frozen compositions, and methods of making them.
    Type: Application
    Filed: September 6, 2019
    Publication date: June 24, 2021
    Applicant: Bavarian Nordic A/S
    Inventors: Katrine Kjaer, Kerstin Mammeri
  • HEPATITIS B VACCINE TRANSNASAL ADMINISTRATION SYSTEM
    Publication number: 20210187101
    Abstract: The present invention relates to a rhinovaccination system for preventing and treating hepatitis B, comprising a hepatitis B vaccine composition for administration to nasal mucosa in combination with a medical nozzle device.
    Type: Application
    Filed: June 4, 2019
    Publication date: June 24, 2021
    Inventors: Taizou KAMISHITA, Takashi MIYAZAKI, Yoichi HIASA, Fazle Akbar SHEIKH MOHAMMAD, Osamu YOSHIDA, Julio Cesar AGUILAR RUBIDO, Gerardo Enrique GUILLEN NIETO, Eduardo PENTON ARIAS
  • METHOD OF OBTAINING A POLYEPITOPIC PROTEIN AND POLYEPITOPIC DNA VECTOR
    Publication number: 20210187102
    Abstract: The present invention is directed to a method of manufacturing a polyepitopic protein comprising the steps of cloning a blunt-ended DNA sequence by encoding the epitope that is to be cloned into a DNA vector recognized by the endonuclease Small or the endonuclease Sapl and isolating the polyepitopic protein by transforming a bacterial host cell with such vector, as well as a DNA vector for embodying this method.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 24, 2021
    Inventors: Piotr SKOWRON, Agnieszka ZYLICZ-STACHULA, Olga ZOLNIERKIEWICZ, Malgorzata SKOWRON, Lukasz JANUS, Joanna JEZEWSKA-FRACKOWIAK, Daria KREFFT, Dawid NIDZWORSKI, Kasjan SZEMIAKO, Natalia MACIEJEWSKA, Marta NOWAK, Aneta SZYMANSKA
  • Toothpaste for Delivering Allergens to Oral Mucosa
    Publication number: 20210187103
    Abstract: Pro-toothpaste compositions formulated to receive a volume of allergen solution to provide toothpastes that exhibit efficacy for oral mucosal immunotherapy (OMIT) and acceptable consumer and product stability properties, along with kits of pro-toothpaste, allergen/extracts of allergens, and optionally compounding means and/or specialized toothbrushes are provided. Toothpastes suitable and effective for OMIT and methods for managing allergic symptoms and for reducing risk of allergy in people without symptoms employing the pro-toothpastes, toothpastes and kits of the invention are also disclosed.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Michael Nelson, Erick Berglund
  • VACCINE ADJUVANTS
    Publication number: 20210187104
    Abstract: The present application relates to an adjuvant which is suitable to be used in vaccines or other immunogenic compositions. Specifically, the adjuvant promotes the induction of interleukin-1 (IL-1), type 1 interferons (IFNs), such as IFN?, and IFN?, type 2 interferons, such as IFN? and/or tumour necrosis factor (TNF) response, such as TNF?, and elicits or enhances an immune response, preferably in neonatal, juvenile or paediatric animal and/or human populations.
    Type: Application
    Filed: May 29, 2019
    Publication date: June 24, 2021
    Inventors: Edward LAVELLE, Sarah DOYLE, Ciaran HARTE, Kiva BRENNAN, Kieran MEADE
  • COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
    Publication number: 20210187105
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: December 31, 2020
    Publication date: June 24, 2021
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
    Publication number: 20210187106
    Abstract: Described herein are methods of treating cancer using combinations of Leukemia Inhibitory Factor (LIF)-binding polypeptides and platinum-based antineoplastic agents.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Joan SEOANE SUAREZ, Judit ANIDO FOLGUEIRA, Robin Matthew HALLETT, Patricia Anne GIBLIN, Jeanne MAGRAM, Naimish PANDYA, Robert WASSERMAN, Angus SINCLAIR
  • METHODS OF PREPARING STABLE LIQUID THERAPEUTIC PROTEIN COMPOSITIONS
    Publication number: 20210187107
    Abstract: The invention relates to a method of preparing a stable liquid therapeutic protein pharmaceutical (biopharmaceutical) comprising: a) obtaining an open-ended container comprising a sample, wherein the sample is a therapeutic protein in a solution; b) freezing the sample; c) applying a vacuum while the sample is frozen and; d) sealing the open end of the container while the sample is frozen and while the vacuum is applied to obtain the liquid therapeutic protein composition.
    Type: Application
    Filed: August 26, 2019
    Publication date: June 24, 2021
    Inventors: Wasfi Abdel Karim ALAZZAM, Conor Robert LAKE, Vakhtang Vladimir LOLADZE
  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS
    Publication number: 20210187108
    Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
    Type: Application
    Filed: June 25, 2020
    Publication date: June 24, 2021
    Inventors: Yimin Qian, Hanqing Dong, Jing Wang, Michael Berlin, Andrew P. Crew, Craig M. Crews
  • DEVICES AND METHODS AND AGENT-ASSISTED MEDICAL PROCEDURES
    Publication number: 20210187109
    Abstract: Various embodiments of bulking or cushioning agents or material and related medical devices and methods are disclosed. For example, a method of performing a medical procedure in a tract of a body may include injecting a material in a liquid phase proximate a target site between a first tissue layer and a second tissue layer, allowing the material to transition from the liquid phase to the gel phase in response to a raise in temperature of the material to approximately at or above the predetermined temperature, and performing a surgical procedure on the target site. The material may have the liquid phase at temperatures below a predetermined temperature and a gel phase at temperature approximately at or above the predetermined temperature.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 24, 2021
    Inventors: Paul Scopton, Samuel Zhong, Yem Chin
  • SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS
    Publication number: 20210187110
    Abstract: Healthcare formulations, including, inventive surfactants, Active ingredient formulated as solids, liquids, or emulsions. The present disclosure provides formulations of healthcare products, such as: prescription drugs, over the counter drugs; minerals, herbal, and/or vitamin supplements; drugs administered in hospitals, clinics, physician's office, and places of palliative care; vaccines, tissue, organ, and cell transplants and/or grafts and/or infusions; and wound care formulations including topical ointments, lotions, cleaners, wipes, bandages, and dressings. The Active may be included in the formulations as a solute, a solvent, a particle, or an oil immiscible component of the formulation. The Active may be included in tablets, capsules, tinctures, liquids, or emulsions. Inventive healthcare formulations include formulations suitable for administration orally, topically, and/or by injection.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 24, 2021
    Inventor: Edward Asirvatham
  • COMPOSITIONS AND METHODS FOR DISRUPTING A MACROPHAGE NETWORK
    Publication number: 20210187111
    Abstract: Described herein are methods and compositions for disrupting a macrophage network. Described herein are targeting agents capable of targeting one or more cells of a macrophage network. Methods for treating various diseases, such as cancer and granulomatous diseases are provided.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 24, 2021
    Inventors: Faith BARNETT, Mauricio ROSENFELD
  • IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210187112
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Application
    Filed: March 5, 2021
    Publication date: June 24, 2021
    Inventors: Darrell Irvine, Haipeng Liu
  • CHOLIX-DERIVED CARRIERS FOR ORAL DELIVERY OF HETEROLOGOUS PAYLOAD
    Publication number: 20210187113
    Abstract: The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
    Type: Application
    Filed: December 21, 2020
    Publication date: June 24, 2021
    Inventors: Thomas Carl Hunter, Randall J. Mrsny, Weijun Feng, Tahir Mahmood, Charles Olsen, Sally Postlethwaite
  • NOVEL LINKER, PREPARATION METHOD, AND APPLICATION THEREOF
    Publication number: 20210187114
    Abstract: Provided in the present invention is a linker and a preparation method thereof, wherein one end of the linker may covalently link a small molecule compound and the like and the other end may specifically and covalently link a targeting substance site under the action of Sortase enzyme. The linker of the present invention can be used to prepare a targeting drug conjugate.
    Type: Application
    Filed: December 28, 2020
    Publication date: June 24, 2021
    Applicant: Genequantum Healtcare (Suzhou) Co., LTD.
    Inventors: Gang QIN, Tan CHUBING, Yuan JINDUO, Lu JIANG
  • Immunoconjugates Targeting EGFR
    Publication number: 20210187115
    Abstract: The invention provides an immunoconjugate of formula: (I), or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 50, “Adj” is an adjuvant moiety, and “Ab” is an antibody construct that has an antigen binding domain that binds EGFR. The invention also provides compositions comprising the immunoconjugate. The invention further provides methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: August 29, 2019
    Publication date: June 24, 2021
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Michael N. Alonso, Edgar George Engleman, David Y. Jackson, Arthur Lee, Shelley Erin Ackerman
  • COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
    Publication number: 20210187116
    Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 24, 2021
    Inventors: Andrew John GEALL, Venkata Ramana DOPPALAPUDI, David Sai-Ho CHU, Michael Caramian COCHRAN, Michael HOOD, Beatrice Diana DARIMONT, Rob BURKE, Yunyu SHI, Gulin Erdogan MARELIUS, Barbora MALECOVA
  • PYRROLOBENZODIAZEPINE CONJUGATES
    Publication number: 20210187117
    Abstract: A conjugate of formula (I), wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R10 is OH, and R11 is formula (A): p is an integer of from 1 to 20.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 24, 2021
    Inventors: Philip Wilson Howard, Elizabeth Dunny, Luke Masterson
  • ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
    Publication number: 20210187118
    Abstract: The present disclosure relates to antibody drug conjugates directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody. The conjugates consist of exatecan derivatives coupled to the anti MUC1 antibodies.
    Type: Application
    Filed: May 17, 2019
    Publication date: June 24, 2021
    Applicant: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK, Akiko NAGASE
  • Drug-Conjugates, Conjugation Methods, And Uses Thereof
    Publication number: 20210187119
    Abstract: In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu, Alexander Wilhelm Chucholowski
  • PEPTIDE-NANOPARTICLE CONJUGATES
    Publication number: 20210187120
    Abstract: Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of ?-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient.
    Type: Application
    Filed: October 29, 2020
    Publication date: June 24, 2021
    Inventors: Seungpyo Hong, Woo-jin Jeong